Min Liang - Search Results

Year	Number of Results
2001	1
2002	3
2003	11
2004	8
2005	1
2006	1
2007	6
2008	11
2009	14
2010	15
2011	12
2012	19
2013	18
2014	17
2015	20
2016	28
2017	27
2018	27
2019	35
2020	50
2021	70
2022	63
2023	62
2024	23

1

Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.

McDermott MSJ, O'Brien NA, Hoffstrom B, Gong K, Lu M, Zhang J, Luo T, Liang M, Jia W, Hong JJ, Chau K, Davenport S, Xie B, Press MF, Panayiotou R, Handly-Santana A, Brugge JS, Presta L, Glaspy J, Slamon DJ. McDermott MSJ, et al. Among authors: liang m. Clin Cancer Res. 2023 Jun 1;29(11):2131-2143. doi: 10.1158/1078-0432.CCR-22-2981. Clin Cancer Res. 2023. PMID: 36884217 Free PMC article. Clinical Trial.

2

TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance.

Ma X, Jia S, Wang G, Liang M, Guo T, Du H, Li S, Li X, Huangfu L, Guo J, Xing X, Ji J. Ma X, et al. Among authors: liang m. Signal Transduct Target Ther. 2023 Jun 26;8(1):246. doi: 10.1038/s41392-023-01450-3. Signal Transduct Target Ther. 2023. PMID: 37357254 Free PMC article.

3

Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial.

Hou FF, Xie D, Wang J, Xu X, Yang X, Ai J, Nie S, Liang M, Wang G, Jia N; MAIN Trial Investigators. Hou FF, et al. Among authors: liang m. JAMA Netw Open. 2023 Feb 1;6(2):e2254054. doi: 10.1001/jamanetworkopen.2022.54054. JAMA Netw Open. 2023. PMID: 36745456 Free article. Clinical Trial.

4

Oncorine, the World First Oncolytic Virus Medicine and its Update in China.

Liang M. Liang M. Curr Cancer Drug Targets. 2018;18(2):171-176. doi: 10.2174/1568009618666171129221503. Curr Cancer Drug Targets. 2018. PMID: 29189159 Review.

5

CircRNA hsa_circRNA_104348 promotes hepatocellular carcinoma progression through modulating miR-187-3p/RTKN2 axis and activating Wnt/β-catenin pathway.

Huang G, Liang M, Liu H, Huang J, Li P, Wang C, Zhang Y, Lin Y, Jiang X. Huang G, et al. Among authors: liang m. Cell Death Dis. 2020 Dec 14;11(12):1065. doi: 10.1038/s41419-020-03276-1. Cell Death Dis. 2020. PMID: 33311442 Free PMC article.

6

Bilirubin gates the TRPM2 channel as a direct agonist to exacerbate ischemic brain damage.

Liu HW, Gong LN, Lai K, Yu XF, Liu ZQ, Li MX, Yin XL, Liang M, Shi HS, Jiang LH, Yang W, Shi HB, Wang LY, Yin SK. Liu HW, et al. Among authors: liang m. Neuron. 2023 May 17;111(10):1609-1625.e6. doi: 10.1016/j.neuron.2023.02.022. Epub 2023 Mar 14. Neuron. 2023. PMID: 36921602 Free PMC article.

7

Translational Pharmacokinetic/Pharmacodynamic Model for mRNA-3927, an Investigational Therapeutic for the Treatment of Propionic Acidemia.

Attarwala H, Lumley M, Liang M, Ivaturi V, Senn J. Attarwala H, et al. Among authors: liang m. Nucleic Acid Ther. 2023 Apr;33(2):141-147. doi: 10.1089/nat.2022.0036. Epub 2022 Dec 27. Nucleic Acid Ther. 2023. PMID: 36577040 Free PMC article.

8

Rehabilitation programme including EMG-biofeedback- assisted pelvic floor muscle training for rectus diastasis after childbirth: a randomised controlled trial.

Liang P, Liang M, Shi S, Liu Y, Xiong R. Liang P, et al. Among authors: liang m. Physiotherapy. 2022 Dec;117:16-21. doi: 10.1016/j.physio.2022.05.001. Epub 2022 May 17. Physiotherapy. 2022. PMID: 36219918 Clinical Trial.

9

A Meta-Analysis of Incidence of Catheter-Related Bloodstream Infection with Midline Catheters and Peripherally Inserted Central Catheters.

Chen X, Liang M. Chen X, et al. Among authors: liang m. J Healthc Eng. 2022 Mar 12;2022:6383777. doi: 10.1155/2022/6383777. eCollection 2022. J Healthc Eng. 2022. PMID: 35313516 Free PMC article.

10

Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.

O'Brien NA, McDermott MSJ, Zhang J, Gong KW, Lu M, Hoffstrom B, Luo T, Ayala R, Chau K, Liang M, Madrid AM, Donahue TR, Glaspy JA, Presta L, Slamon DJ. O'Brien NA, et al. Among authors: liang m. Mol Cancer Ther. 2023 Dec 1;22(12):1365-1375. doi: 10.1158/1535-7163.MCT-23-0353. Mol Cancer Ther. 2023. PMID: 37788341

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

477 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

477 results

Results by year